Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
+0.01 (0.17%)
Real-time:   1:49PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.90 - 6.07
52 week 5.05 - 8.48
Open 6.07
Vol / Avg. 28,895.00/28,318.00
Mkt cap 94.76M
P/E     -
Div/yield     -
EPS -1.40
Shares 15.64M
Beta 1.17
Inst. own 25%
May 12, 2017
Q1 2017 Chembio Diagnostics Inc Earnings Release (Estimated)
May 9, 2017
Q1 2017 Chembio Diagnostics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -25.54% -74.69%
Operating margin -25.75% -42.37%
EBITD margin - -36.00%
Return on average assets -31.26% -64.49%
Return on average equity -37.52% -76.64%
Employees 131 -
CDP Score - -


3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

Sharon Klugewicz Acting Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 64
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Gail S. Page Director
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters